Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
AstraZeneca
Moodys
Johnson and Johnson
Harvard Business School

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Shire Llc Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for SHIRE LLC, and when can generic versions of SHIRE LLC drugs launch?

SHIRE LLC has four approved drugs.

There are two US patents protecting SHIRE LLC drugs.

There are sixty-two patent family members on SHIRE LLC drugs in thirty-one countries.

Summary for Shire Llc

Drugs and US Patents for Shire Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-003 Nov 23, 2005 AB RX Yes No 7,381,428   See Pricing   See Pricing
Shire Llc SALURON hydroflumethiazide TABLET;ORAL 011949-001 Approved Prior to Jan 1, 1982 DISCN Yes No   See Pricing   See Pricing
Shire Llc PROAMATINE midodrine hydrochloride TABLET;ORAL 019815-002 Sep 6, 1996 DISCN Yes No   See Pricing   See Pricing
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-002 Oct 26, 2004 AB RX Yes No 7,381,428   See Pricing   See Pricing
Shire Llc AGRYLIN anagrelide hydrochloride CAPSULE;ORAL 020333-002 Mar 14, 1997 DISCN Yes No   See Pricing   See Pricing
Shire Llc PROAMATINE midodrine hydrochloride TABLET;ORAL 019815-001 Sep 6, 1996 DISCN Yes No   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Shire Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-002 Oct 26, 2004 5,968,976   See Pricing
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-004 Nov 23, 2005 5,968,976   See Pricing
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-001 Oct 26, 2004 5,968,976   See Pricing
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-003 Nov 23, 2005 5,968,976   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SHIRE LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Powder 750 mg and 1000 mg ➤ Subscribe 2015-11-25
➤ Subscribe Chewable Tablet 500 mg, 750 mg and 1000 mg ➤ Subscribe 2008-10-27
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
McKinsey
Dow
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.